Persisting SARS‐CoV‐2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature

Summary SARS‐CoV‐2 infection can cause severe pneumonia (COVID‐19). There is evidence that patients with comorbidities are at higher risk of a severe disease course. The role of immunosuppression in the disease course is not clear. In the present report, we first describe two cases of persisting SAR...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2020-07, Vol.190 (2), p.185-188
Hauptverfasser:	Tepasse, Phil‐Robin, Hafezi, Wali, Lutz, Mathias, Kühn, Joachim, Wilms, Christian, Wiewrodt, Rainer, Sackarnd, Jan, Keller, Martin, Schmidt, Hartmut H., Vollenberg, Richard
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged B-Lymphocytes - pathology Betacoronavirus Coronavirus Infections - complications Coronavirus Infections - pathology COVID-19 Fatal Outcome Hematology Humans Immunocompromised Host Immunosuppression Immunotherapy Literature reviews Lymphoma, Large B-Cell, Diffuse - complications Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Mantle-Cell - complications Lymphoma, Mantle-Cell - drug therapy Male Middle Aged Monoclonal antibodies Pandemics pneumonia Pneumonia, Viral - complications Pneumonia, Viral - pathology Rituximab Rituximab - administration & dosage SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Short Report viraemia Viremia Viremia - diagnosis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary SARS‐CoV‐2 infection can cause severe pneumonia (COVID‐19). There is evidence that patients with comorbidities are at higher risk of a severe disease course. The role of immunosuppression in the disease course is not clear. In the present report, we first describe two cases of persisting SARS‐CoV‐2 viraemia with fatal outcome in patients after rituximab therapy.
ISSN:	0007-1048 1365-2141
DOI:	10.1111/bjh.16896